|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Register now for the FSP Summer Anatomic Pathology Conference
Register here or go to www.flpath.org and click on the Summer Meeting tab to secure all information on speakers, program, hotel, Boca Raton and registration.
Andrew E. Rosenberg, M.D.
University of Miami Health Service
William Westra, M.D.
Johns Hopkins Medical Institute
Cesar Moran, M.D.
The University of Texas MD Anderson Cancer Center
NIH's drug lab is shut down after FDA finds quality failures
A U.S.-run laboratory that makes drugs for the National Institutes of Health's clinical trials failed a government quality inspection and will be temporarily shut down. The U.S. Food and Drug Administration, the government regulator that spends much of its time making sure drug companies follow exacting quality standards, inspected the NIH's Pharmaceutical Development Section. The lab makes drugs that are used in government-sponsored clinical trials at the NIH hospital in Bethesda, Maryland. Operations at the lab have been suspended.
Some ACOs show improved patient outcomes and lower costs: Still unclear how payment will be made for clinical lab tests
Accountable care organizations are not only growing in number but some ACOs are also reporting outcomes that indicate their value-based reimbursement model may produce better results for patients than traditional fee-for-service (FFS) medicine.
For the pathology profession, this news further emphasizes the need for medical laboratories and group pathology practices to have a seat at the table during the organization of ACOs so they can make a clinical contribution and negotiate adequate reimbursement from the fixed fees paid to ACOs. At the moment, one big question for labs is how they are to be paid under a value-based reimbursement model.
American Board of Pathology elect 2016 Trustee
The American Board of Pathology (ABP) of Tampa, Florida is pleased to announce the election of Jeffrey Goldstein, M.D. as a Trustee for a term beginning in 2016.
Dr. Goldstein has been the pediatric pathologist at Wolfson Children's Hospital in Jacksonville, Florida, for nearly 27 years and has served as Chief of the Independent Service of Pathology and as Medical Director of Laboratories and the Transfusion and Apheresis Service for Baptist Health. In August, he will be joining the faculty at David Geffen School of Medicine, UCLA and will be Clinical Chief of Pediatric Pathology at Mattel Children's Hospital and Ronald Reagan UCLA Medical Center.
To be sued less, doctors should consider talking to patients more
The New York Times
Doctors call it defensive medicine. They order extra tests, perform extra procedures or push for more office visits because they think that without them, they're at greater risk of being sued. But studies don't support the notion that this extra precaution reduces their risk. What might help physicians avoid being sued is getting along better with their patients. Or at least, they could become better communicators.
People want genome data, even if it's uninterpretable
The largest study to date of attitudes toward the use of genomic information shows that the majority of people want access to results from genome sequencing, even if these are not directly related to the condition for which the analysis has been undertaken. This applies even when the data are not health-related or are simply "raw."
Politically correct medical schools
Ask any premed student what they fear most and the answer will always be the MCAT, or Medical College Admission Test. After 25 years, the MCAT is being revised, becoming longer (by three hours) and covering a broader range of topics than simply chemistry, physics and biology. One quarter of the new test covers "psychology, sociology and the biological foundations of behavior." More specifically, students will be tested on "social inequality, class consciousness, racial and ethnic identity, institutionalized racism and discrimination, and power, privilege and prestige."
Miss an issue of Pathology Today? Click here to visit the Pathology Today archive page.
Choosing telehealth for growth: Evaluating logistics and operations
By Karen R. Thomas
One of the first steps toward choosing the right telehealth program for your business is to determine the needs of your customers, clients and/or patients so you can assess how telehealth will help them achieve better health outcomes. However, an equally important step in choosing the right telehealth program is to evaluate the logistics that will be required. Here are some important considerations when planning to add telehealth to your business.
Lung cancer blood test steps closer with new biomarker discovery
Medical News Today
It is estimated that more than 158,000 people in the U.S. will die from lung cancer this year, emphasizing the need for earlier detection of the disease, leading to better treatment outcomes. Now, researchers have discovered a biomarker that could lead to a highly accurate blood test for early detection of nonsmall cell lung cancer — the most common form of the disease.
Gene panel confirms high rate of BRCA mutations
A diagnostic panel that looks for mutations in 25 genes determined that women with triple-negative breast cancer had about 50 percent more "dangerous mutations" than women with hormone-sensitive cancers, researchers said here.
"The overall mutation prevalence in patients with triple-negative breast cancer was 14.7 percent compared with 9.2 percent in patients with other types of breast cancer," reported John Sandbach, M.D., of Texas Oncology Austin, and colleagues in a poster presentation at the American Society of Clinical Oncology annual meeting.
Disclaimer: The authors, editors, and the Florida Society of Pathologists (FSP) Executive Committee affiliated with "Florida Pathology Today" e-Newsletter cannot and do not warrant the completeness, accuracy, non-infringement, merchantability, timeliness or fitness for a particular purpose of the information or views contained within this publication, or available through the links provided within articles contained within this publication.
FSP has no control over and does not officially endorse the content of the information available on the links contained in the "Florida Pathology Today" or links imbedded in articles within the "Florida Pathology Today." These links are provided as a courtesy only. Linked sites are not a part of the "Florida Pathology Today." The owners of those linked sites, and not FSP, own the intellectual property rights to the material on the linked sites. FSP cannot certify the accuracy of material published on linked sites. Additionally, the contents of this e-Newsletter and the above referenced links, including any advice, suggestions, and/or recommendations have NOT been generated as part of any professional evaluation.
The authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" e-Newsletter shall not be liable to anyone for any loss or injury caused in whole or in part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting or delivering this e-Newsletter and any information included in this e-Newsletter.
Under no circumstances will the authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" be liable to you or anyone else for any decision made or any action taken by you or anyone else in reliance on such information or view, or for any incidental, consequential, special, or similar damages even if advised of the possibility of such damages.
The above warranties are the only warranties of any kind either expressed or implied, including warranties of merchantability or fitness for any particular purpose.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063